Loading...
An emerging treatment option for glaucoma: Rho kinase inhibitors
Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in Phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoske...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4025933/ https://ncbi.nlm.nih.gov/pubmed/24872673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S41000 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|